GSK showcases progress in liver portfolio at AASLD 2026
November 05, 2026
November 05, 2026
LONDON, England, Nov. 5 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:
* * *
GSK showcases progress in liver portfolio at AASLD 2026
*
* Hibsago (bepirovirsen) treatment for patients with chronic hepatitis B (CHB) reinforced by new long-term dataset
* Further Hibsago research on surface antigen (HBsAg) reduction, retreatment modelling and functional . . .
* * *
GSK showcases progress in liver portfolio at AASLD 2026
*
* Hibsago (bepirovirsen) treatment for patients with chronic hepatitis B (CHB) reinforced by new long-term dataset
* Further Hibsago research on surface antigen (HBsAg) reduction, retreatment modelling and functional . . .
